Christopher Posner - 29 Oct 2021 Form 4 Insider Report for Cara Therapeutics, Inc. (CARA)

Role: Director, Senior Advisor
Signature: /s/ Christopher Posner
Issuer symbol: CARA
Transactions as of: 29 Oct 2021
Transactions value $: $0
Form type: 4
Filing time: 03 Nov 2021, 08:15:20 UTC
Previous filing: 07 Jun 2021
Next filing: 01 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CARA	Common Stock	Award	$0	+5.94K	+36.91%	$0.00	22K	29 Oct 2021	Direct	F1
transaction	CARA	Common Stock	Award	$0	+142K	+644.37%	$0.00	164K	29 Oct 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CARA	Stock Option (Right to Buy)	Award	$0	+566K		$0.00	566K	29 Oct 2021	Common Stock	566K	$16.83	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to an Employment Agreement, dated October 29, 2021, between the Reporting Person and the Issuer, whereby the Reporting Person is employed as a Senior Advisor to the Issuer effective October 29, 2021 and as President and Chief Executive Officer of the Issuer effective November 9, 2021 (the "Employment Agreement"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs will vest in full on March 31, 2022, subject to the Reporting Person's continued service to the Issuer on such date.
F2	Represents the number of shares underlying RSUs granted to the Reporting Person pursuant to the Employment Agreement. Each RSU represents the contingent right to receive one share of common stock of the Issuer. 25% of the RSUs will vest on October 29, 2022 and the remainder will vest over the following 12 equal quarterly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date.
F3	25% of the shares will vest and become exercisable on October 29, 2022 and the remainder will vest over the following 12 equal quarterly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date. These options were granted to the Reporting Person pursuant to the Employment Agreement.